3-Bromo-4-methylbenzotrifluoride | CAS:66417-30-9

We serve 3-Bromo-4-methylbenzotrifluoride CAS:66417-30-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Bromo-4-methylbenzotrifluoride

Chemical Name:  3-Bromo-4-methylbenzotrifluoride
CAS.NO:66417-30-9
Synonyms:2-bromo-1-methyl-4-(trifluoromethyl)benzene;
Molecular Formula: C8H6BrF3
Molecular Weight:239.03200
 
Physical and Chemical Properties:
Density:1.538g/cm3
Melting point:/
Boiling point:199.4ºC at 760 mmHg
Flash point:84.1ºC
Index of Refraction:1.474
 
Specification:
Appearance:clear colourless liquid
Purity:≥98.0%
 
Packing: as customer request
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:  Applicationd as Pharmaceutical intermediates



Contact us for information like 3-Bromo-4-methylbenzotrifluoride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-1-methyl-4-(trifluoromethyl)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-4-methylbenzotrifluoride Use and application,3-Bromo-4-methylbenzotrifluoride technical grade,usp/ep/jp grade.


Related News: Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.2',3',5'-Tri-O-acetyl-D-adenosine manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.Methyltriacetoxysilane supplier ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.3-Chloro-2-iodopyridine vendor With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.The two institutes that discovered Shuanghuanglian’s alleged ability to “inhibit” the coronavirus are both state-run bodies.